A E Bowyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8820746/publications.pdf

Version: 2024-02-01

24 papers	499 citations	687363 13 h-index	677142 22 g-index
24 all docs	24 docs citations	24 times ranked	440 citing authors

#	Article	IF	Citations
1	External quality assessment for oneâ€stage and chromogenic factor IX assays in samples containing Alprolix (rFIXFc) or Idelvion (rIXâ€FP) and evidence that UK National External Quality Assessment Scheme for blood coagulation samples are commutable with patient samples. International Journal of Laboratory Hematology, 2022, . . .	1.3	0
2	Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab. British Journal of Haematology, 2022, 197, 349-358.	2.5	3
3	Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctorsâ€™ Organisation guideline. Haemophilia, 2022, 28, 515-519.	2.1	7
4	Laboratory issues in gene therapy and emicizumab. Haemophilia, 2021, 27, 142-147.	2.1	19
5	Measurement of antifactor VIII antibody titre in the presence of emicizumab; Use of chromogenic Bethesda assays. International Journal of Laboratory Hematology, 2021, 43, O204-O206.	1.3	4
6	Principles of care for acquired hemophilia. European Journal of Haematology, 2021, 106, 762-773.	2.2	11
7	Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing. Journal of Thrombosis and Haemostasis, 2021, 19, 2857-2861.	3.8	11
8	Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctorsâ€™ Organisation guideline. Haemophilia, 2020, 26, 6-16.	2.1	31
9	Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia, 2020, 26, 151-155.	2.1	44
10	Crossâ€reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A. Haemophilia, 2020, 26, 1181-1186.	2.1	5
11	Effects of emicizumab on APTT, oneâ€stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia, 2020, 26, 536-542.	2.1	34
12	A costâ€effective approach to factor assay calibration using a truncated live calibration curve. International Journal of Laboratory Hematology, 2019, 41, 679-683.	1.3	4
13	Measurement of extended halfâ€life recombinant factor IX products in clinical practice. International Journal of Laboratory Hematology, 2019, 41, e46-e49.	1.3	13
14	Evaluation of a semiâ€automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 790-799.	2.3	27
15	Role of chromogenic assays in haemophilia A and B diagnosis. Haemophilia, 2018, 24, 578-583.	2.1	13
16	Measuring <scp>FVIII</scp> activity of glycopegylated recombinant factor <scp>VIII</scp>, N8â€<scp>GP</scp>, with commercially available oneâ€stage clotting and chromogenic assay kits: a twoâ€centre study. Haemophilia, 2017, 23, 458-465.	2.1	41
17	Qualification of a select oneâ€stage activated partial thromboplastin timeâ€based clotting assay and two chromogenic assays for the postâ€administration monitoring of nonacog beta pegol. Journal of Thrombosis and Haemostasis, 2017, 15, 1901-1912.	3.8	30
18	The coagulation laboratory monitoring of Afstyla singleâ€chain <scp>FVIII</scp> concentrate. Haemophilia, 2017, 23, e469-e470.	2.1	20

#	Article	IF	Citations
19	Von Willebrand factor activity assay errors. Haemophilia, 2016, 22, e74-6.	2.1	4
20	Measuring factor IX activity of nonacog beta pegol with commercially available oneâ€stage clotting and chromogenic assay kits: a twoâ€center study. Journal of Thrombosis and Haemostasis, 2016, 14, 1428-1435.	3.8	51
21	Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica, 2013, 98, 1980-1987.	3.5	48
22	A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of Von Willebrand disease. Thrombosis Research, 2011, 127, 341-344.	1.7	13
23	The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies. International Journal of Laboratory Hematology, 2011, 33, 154-158.	1.3	55
24	The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal. International Journal of Laboratory Hematology, 2011, 33, 212-218.	1.3	11